Chongqing Genrix Biopharmaceutical Co Ltd

Company Profile

• Business description

  Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

• Contact

  No. 699, Maliu Avenue
  Area A, Building 2
  International Bio City
  Banan
  Chongqing401338
  CHN

  T: +86 2361758666

  http://www.genrixbio.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  743